A citation-based method for searching scientific literature

Philip J Rosenfeld, David M Brown, Jeffrey S Heier, David S Boyer, Peter K Kaiser, Carol Y Chung, Robert Y Kim. N Engl J Med 2006
Times Cited: 4055







List of co-cited articles
498 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.
Jeffrey S Heier, David M Brown, Victor Chong, Jean-Francois Korobelnik, Peter K Kaiser, Quan Dong Nguyen, Bernd Kirchhof, Allen Ho, Yuichiro Ogura, George D Yancopoulos,[...]. Ophthalmology 2012
36

Ranibizumab versus verteporfin for neovascular age-related macular degeneration.
David M Brown, Peter K Kaiser, Mark Michels, Gisele Soubrane, Jeffrey S Heier, Robert Y Kim, Judy P Sy, Susan Schneider. N Engl J Med 2006
35

Ranibizumab and bevacizumab for neovascular age-related macular degeneration.
Daniel F Martin, Maureen G Maguire, Gui-shuang Ying, Juan E Grunwald, Stuart L Fine, Glenn J Jaffe. N Engl J Med 2011
22

Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis.
Wan Ling Wong, Xinyi Su, Xiang Li, Chui Ming G Cheung, Ronald Klein, Ching-Yu Cheng, Tien Yin Wong. Lancet Glob Health 2014
22

Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study.
David M Brown, Mark Michels, Peter K Kaiser, Jeffrey S Heier, Judy P Sy, Tsontcho Ianchulev. Ophthalmology 2009
950
15

HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.
Pravin U Dugel, Adrian Koh, Yuichiro Ogura, Glenn J Jaffe, Ursula Schmidt-Erfurth, David M Brown, Andre V Gomes, James Warburton, Andreas Weichselberger, Frank G Holz. Ophthalmology 2020
272
14

Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP).
Soraya Rofagha, Robert B Bhisitkul, David S Boyer, SriniVas R Sadda, Kang Zhang. Ophthalmology 2013
649
13

Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration.
Frank G Holz, Ramin Tadayoni, Stephen Beatty, Alan Berger, Matteo G Cereda, Rafael Cortez, Carel B Hoyng, Philip Hykin, Giovanni Staurenghi, Stephanie Heldner,[...]. Br J Ophthalmol 2015
340
12

Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results.
Daniel F Martin, Maureen G Maguire, Stuart L Fine, Gui-shuang Ying, Glenn J Jaffe, Juan E Grunwald, Cynthia Toth, Maryann Redford, Frederick L Ferris. Ophthalmology 2012
11

Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials.
Maureen G Maguire, Daniel F Martin, Gui-Shuang Ying, Glenn J Jaffe, Ebenezer Daniel, Juan E Grunwald, Cynthia A Toth, Frederick L Ferris, Stuart L Fine. Ophthalmology 2016
374
9

Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies.
Ursula Schmidt-Erfurth, Peter K Kaiser, Jean-François Korobelnik, David M Brown, Victor Chong, Quan Dong Nguyen, Allen C Ho, Yuichiro Ogura, Christian Simader, Glenn J Jaffe,[...]. Ophthalmology 2014
521
9

Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab Using a Treat-and-Extend Regimen: FLUID Study 24-Month Results.
Robyn H Guymer, Caroline M Markey, Ian L McAllister, Mark C Gillies, Alex P Hunyor, Jennifer J Arnold. Ophthalmology 2019
132
9

Treat-and-Extend versus Monthly Regimen in Neovascular Age-Related Macular Degeneration: Results with Ranibizumab from the TREND Study.
Rufino Silva, András Berta, Michael Larsen, Wayne Macfadden, Chrystel Feller, Jordi Monés. Ophthalmology 2018
140
9

HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration.
Michael A Singer, Carl C Awh, SriniVas Sadda, William R Freeman, Andrew N Antoszyk, Pamela Wong, Lisa Tuomi. Ophthalmology 2012
261
8

Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA).
Ursula Schmidt-Erfurth, Victor Chong, Anat Loewenstein, Michael Larsen, Eric Souied, Reinier Schlingemann, Bora Eldem, Jordi Monés, Gisbert Richard, Francesco Bandello. Br J Ophthalmol 2014
308
8

The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis.
Tien Y Wong, Usha Chakravarthy, Ronald Klein, Paul Mitchell, Gergana Zlateva, Ronald Buggage, Kyle Fahrbach, Corey Probst, Isabella Sledge. Ophthalmology 2008
388
8

Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.
Quan Dong Nguyen, David M Brown, Dennis M Marcus, David S Boyer, Sunil Patel, Leonard Feiner, Andrea Gibson, Judy Sy, Amy Chen Rundle, J Jill Hopkins,[...]. Ophthalmology 2012
8

Age-related macular degeneration.
Paul Mitchell, Gerald Liew, Bamini Gopinath, Tien Y Wong. Lancet 2018
428
8

Effect of Ranibizumab and Aflibercept on Best-Corrected Visual Acuity in Treat-and-Extend for Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial.
Mark C Gillies, Alex P Hunyor, Jennifer J Arnold, Robyn H Guymer, Sebastian Wolf, Paul Ng, Francois L Pecheur, Ian L McAllister. JAMA Ophthalmol 2019
64
10

Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration.
Gui-shuang Ying, Jiayan Huang, Maureen G Maguire, Glenn J Jaffe, Juan E Grunwald, Cynthia Toth, Ebenezer Daniel, Michael Klein, Dante Pieramici, John Wells,[...]. Ophthalmology 2013
215
7

Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1.
Carl D Regillo, David M Brown, Prema Abraham, Huibin Yue, Tsontcho Ianchulev, Susan Schneider, Naveed Shams. Am J Ophthalmol 2008
626
7


Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial.
Usha Chakravarthy, Simon P Harding, Chris A Rogers, Susan M Downes, Andrew J Lotery, Sarah Wordsworth, Barnaby C Reeves. Ophthalmology 2012
585
7

Prevalence of Age-Related Macular Degeneration in Europe: The Past and the Future.
Johanna M Colijn, Gabriëlle H S Buitendijk, Elena Prokofyeva, Dalila Alves, Maria L Cachulo, Anthony P Khawaja, Audrey Cougnard-Gregoire, Bénédicte M J Merle, Christina Korb, Maja G Erke,[...]. Ophthalmology 2017
201
7


Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.
Brandon G Busbee, Allen C Ho, David M Brown, Jeffrey S Heier, Ivan J Suñer, Zhengrong Li, Roman G Rubio, Phillip Lai. Ophthalmology 2013
339
7

Age-Related Macular Degeneration Preferred Practice Pattern®.
Christina J Flaxel, Ron A Adelman, Steven T Bailey, Amani Fawzi, Jennifer I Lim, G Atma Vemulakonda, Gui-Shuang Ying. Ophthalmology 2020
59
11

Adherence to ranibizumab treatment for neovascular age-related macular degeneration in real life.
Katharina M Droege, Philipp S Muether, Manuel M Hermann, Albert Caramoy, Ulrike Viebahn, Bernd Kirchhof, Sascha Fauser. Graefes Arch Clin Exp Ophthalmol 2013
65
9

EXIT STRATEGY IN A TREAT-AND-EXTEND REGIMEN FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION.
Petra Arendt, Siqing Yu, Marion R Munk, Andreas Ebneter, Sebastian Wolf, Martin S Zinkernagel. Retina 2019
23
26

C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial.
Glenn J Jaffe, Keith Westby, Karl G Csaky, Jordi Monés, Joel A Pearlman, Sunil S Patel, Brian C Joondeph, John Randolph, Harvey Masonson, Kourous A Rezaei. Ophthalmology 2021
68
8

HAWK and HARRIER: Ninety-Six-Week Outcomes from the Phase 3 Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.
Pravin U Dugel, Rishi P Singh, Adrian Koh, Yuichiro Ogura, Georges Weissgerber, Kinfemichael Gedif, Glenn J Jaffe, Ramin Tadayoni, Ursula Schmidt-Erfurth, Frank G Holz. Ophthalmology 2021
80
7

Single-Chain Antibody Fragment VEGF Inhibitor RTH258 for Neovascular Age-Related Macular Degeneration: A Randomized Controlled Study.
Frank G Holz, Pravin U Dugel, Georges Weissgerber, Robin Hamilton, Rufino Silva, Francesco Bandello, Michael Larsen, Andreas Weichselberger, Andreas Wenzel, Anne Schmidt,[...]. Ophthalmology 2016
69
8

Real-world outcomes in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor inhibitors.
Hemal Mehta, Adnan Tufail, Vincent Daien, Aaron Y Lee, Vuong Nguyen, Mehmet Ozturk, Daniel Barthelmes, Mark C Gillies. Prog Retin Eye Res 2018
116
6

Current and upcoming anti-VEGF therapies and dosing strategies for the treatment of neovascular AMD: a comparative review.
Saira Khanna, Rahul Komati, David A Eichenbaum, Ishani Hariprasad, Thomas A Ciulla, Seenu M Hariprasad. BMJ Open Ophthalmol 2019
40
15

TREAT-AND-EXTEND REGIMENS WITH ANTI-VEGF AGENTS IN RETINAL DISEASES: A Literature Review and Consensus Recommendations.
K Bailey Freund, Jean-François Korobelnik, Robert Devenyi, Carsten Framme, John Galic, Edward Herbert, Hans Hoerauf, Paolo Lanzetta, Stephan Michels, Paul Mitchell,[...]. Retina 2015
165
6

Long-term Outcome of Intravitreal Aflibercept Treatment for Neovascular Age-Related Macular Degeneration Using a "Treat-and-Extend" Regimen.
Peter G Traine, Isabel B Pfister, Souska Zandi, Jan Spindler, Justus G Garweg. Ophthalmol Retina 2019
37
13

Treat-and-Extend Therapy Using Aflibercept for Neovascular Age-related Macular Degeneration: A Prospective Clinical Trial.
Francis Char DeCroos, David Reed, Murtaza K Adam, David Salz, Omesh P Gupta, Allen C Ho, Carl D Regillo. Am J Ophthalmol 2017
49
10



Real-World Vision in Age-Related Macular Degeneration Patients Treated with Single Anti-VEGF Drug Type for 1 Year in the IRIS Registry.
Prethy Rao, Flora Lum, Kevin Wood, Craig Salman, Bhavya Burugapalli, Rebecca Hall, Sukhminder Singh, David W Parke, George A Williams. Ophthalmology 2018
75
6

Novel method for analyzing snellen visual acuity measurements.
Ninel Z Gregori, William Feuer, Philip J Rosenfeld. Retina 2010
312
5

The Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration: Results from the Randomized Phase 2 Ladder Clinical Trial.
Peter A Campochiaro, Dennis M Marcus, Carl C Awh, Carl Regillo, Anthony P Adamis, Vladimir Bantseev, Yawen Chiang, Jason S Ehrlich, Signe Erickson, William D Hanley,[...]. Ophthalmology 2019
113
5

Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study.
Ursula Schmidt-Erfurth, Bora Eldem, Robyn Guymer, Jean-François Korobelnik, Reinier O Schlingemann, Ruth Axer-Siegel, Peter Wiedemann, Christian Simader, Margarita Gekkieva, Andreas Weichselberger. Ophthalmology 2011
287
5

Outcomes of Suspending VEGF Inhibitors for Neovascular Age-Related Macular Degeneration When Lesions Have Been Inactive for 3 Months.
Vuong Nguyen, Anagha Vaze, Samantha Fraser-Bell, Jennifer Arnold, Rohan W Essex, Daniel Barthelmes, Mark C Gillies. Ophthalmol Retina 2019
19
26

Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.
Allen C Ho, Brandon G Busbee, Carl D Regillo, Mark R Wieland, Sherri A Van Everen, Zhengrong Li, Roman G Rubio, Phillip Lai. Ophthalmology 2014
210
5

A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration.
Ursula Schmidt-Erfurth, Sebastian M Waldstein. Prog Retin Eye Res 2016
175
5


Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial.
Laurent Kodjikian, Eric H Souied, Gérard Mimoun, Martine Mauget-Faÿsse, Francine Behar-Cohen, Evelyne Decullier, Laure Huot, Gilles Aulagner. Ophthalmology 2013
184
5


Consensus Nomenclature for Reporting Neovascular Age-Related Macular Degeneration Data: Consensus on Neovascular Age-Related Macular Degeneration Nomenclature Study Group.
Richard F Spaide, Glenn J Jaffe, David Sarraf, K Bailey Freund, Srinivas R Sadda, Giovanni Staurenghi, Nadia K Waheed, Usha Chakravarthy, Philip J Rosenfeld, Frank G Holz,[...]. Ophthalmology 2020
169
5


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.